Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H24N2OS |
| Molecular Weight | 340.482 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCNC1=CC=C(C)C2=C1C(=O)C3=C(S2)C=CC=C3
InChI
InChIKey=FBQPGGIHOFZRGH-UHFFFAOYSA-N
InChI=1S/C20H24N2OS/c1-4-22(5-2)13-12-21-16-11-10-14(3)20-18(16)19(23)15-8-6-7-9-17(15)24-20/h6-11,21H,4-5,12-13H2,1-3H3
| Molecular Formula | C20H24N2OS |
| Molecular Weight | 340.482 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Lucanthone is a thioxanthenone DNA intercalator. It inhibits topoisomerases and the dual function base excision repair enzyme apurinic endonuclease 1. Lucanthone has been devised for the treatment of schistosomiasis. It is also an antitumor agent. Lucanthone was being developed by Spectrum Pharmaceuticals for the treatment of malignant brain tumours.
Originator
Approval Year
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
96 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9989518/ |
10 mg/kg 1 times / 2 days steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LUCANTHONE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. | 2011-02-25 |
|
| 4-(Piperidin-1-yl)-4H-benzo[b]tetra-zolo[1,5-d][1,4]diazepin-5(6H)-one. | 2010-12-04 |
|
| [(1,2,5,6-η)-1,5-Cyclo-octa-diene](1-isopropyl-3-methyl-imidazolin-2-yl-idene)(triphenyl-phosphine)iridium(I) tetra-fluorido-borate dichloro-methane solvate. | 2010-08-18 |
|
| 2-Butyl-11-phenyl-5,10-dihydro-1H-benzo[e]imidazo[1,5-a][1,4]diazepine-1,3(2H)-dione. | 2010-02-13 |
|
| 2-Propyl 3,3-dibromo-2-hydroxy-pyrrolidine-1-carboxyl-ate. | 2010-02-13 |
|
| Radiation resistance in glioma cells determined by DNA damage repair activity of Ape1/Ref-1. | 2010 |
|
| The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. | 2007-04-03 |
|
| Clonogenicity of human leukemic cells protected from cell-lethal agents by heat shock protein 70. | 2005 |
|
| Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. | 2004-08-28 |
|
| Design of small volume HX and triple-resonance probes for improved limits of detection in protein NMR experiments. | 2003-09 |
|
| Abasic sites in DNA of HeLa cells induced by lucanthone. | 2002 |
|
| Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone. | 1999-01-01 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:54:12 GMT 2025
by
admin
on
Mon Mar 31 17:54:12 GMT 2025
|
| Record UNII |
FC6D57000M
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C250
Created by
admin on Mon Mar 31 17:54:12 GMT 2025 , Edited by admin on Mon Mar 31 17:54:12 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
51052
Created by
admin on Mon Mar 31 17:54:12 GMT 2025 , Edited by admin on Mon Mar 31 17:54:12 GMT 2025
|
PRIMARY | |||
|
C83925
Created by
admin on Mon Mar 31 17:54:12 GMT 2025 , Edited by admin on Mon Mar 31 17:54:12 GMT 2025
|
PRIMARY | |||
|
D008154
Created by
admin on Mon Mar 31 17:54:12 GMT 2025 , Edited by admin on Mon Mar 31 17:54:12 GMT 2025
|
PRIMARY | |||
|
1616
Created by
admin on Mon Mar 31 17:54:12 GMT 2025 , Edited by admin on Mon Mar 31 17:54:12 GMT 2025
|
PRIMARY | |||
|
SUB08613MIG
Created by
admin on Mon Mar 31 17:54:12 GMT 2025 , Edited by admin on Mon Mar 31 17:54:12 GMT 2025
|
PRIMARY | |||
|
DTXSID6023230
Created by
admin on Mon Mar 31 17:54:12 GMT 2025 , Edited by admin on Mon Mar 31 17:54:12 GMT 2025
|
PRIMARY | |||
|
207-532-4
Created by
admin on Mon Mar 31 17:54:12 GMT 2025 , Edited by admin on Mon Mar 31 17:54:12 GMT 2025
|
PRIMARY | |||
|
FC6D57000M
Created by
admin on Mon Mar 31 17:54:12 GMT 2025 , Edited by admin on Mon Mar 31 17:54:12 GMT 2025
|
PRIMARY | |||
|
10180
Created by
admin on Mon Mar 31 17:54:12 GMT 2025 , Edited by admin on Mon Mar 31 17:54:12 GMT 2025
|
PRIMARY | |||
|
337
Created by
admin on Mon Mar 31 17:54:12 GMT 2025 , Edited by admin on Mon Mar 31 17:54:12 GMT 2025
|
PRIMARY | |||
|
100000082269
Created by
admin on Mon Mar 31 17:54:12 GMT 2025 , Edited by admin on Mon Mar 31 17:54:12 GMT 2025
|
PRIMARY | |||
|
DB04967
Created by
admin on Mon Mar 31 17:54:12 GMT 2025 , Edited by admin on Mon Mar 31 17:54:12 GMT 2025
|
PRIMARY | |||
|
CHEMBL279014
Created by
admin on Mon Mar 31 17:54:12 GMT 2025 , Edited by admin on Mon Mar 31 17:54:12 GMT 2025
|
PRIMARY | |||
|
m6920
Created by
admin on Mon Mar 31 17:54:12 GMT 2025 , Edited by admin on Mon Mar 31 17:54:12 GMT 2025
|
PRIMARY | Merck Index | ||
|
479-50-5
Created by
admin on Mon Mar 31 17:54:12 GMT 2025 , Edited by admin on Mon Mar 31 17:54:12 GMT 2025
|
PRIMARY | |||
|
LUCANTHONE
Created by
admin on Mon Mar 31 17:54:12 GMT 2025 , Edited by admin on Mon Mar 31 17:54:12 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |